liver

Topline data from a Phase IIa study showed ChemomAb’s (Chemomab) investigational monoclonal antibody, CM-101, met its primary endpoints of safety and tolerability in nonalcoholic steatohepatitis (NASH), the Israel-based biotech reported Tuesday.

Michael Goettler Viatris

Viatris Inc. announced that it has closed its acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. The transaction was first announced on November 7 as part of Viatris’ strategic update. Former Oyster Point Pharma CEO, Jeffrey Nau, Ph.D., MMS, will lead the new division.

Blacksmith Medicines logo

Blacksmith Medicines, Inc. and Forge Therapeutics announced that the companies have signed a definitive merger agreement to leverage their combined chemistry platforms, creating a leading biopharma dedicated to discovering and developing medicines targeting a large class of proteins called metalloenzymes, with initial focus on oncology and infection.

pharmacist

Drugmakers including Pfizer Inc., GlaxoSmithKline PLC, Bristol Myers Squibb, AstraZeneca PLC, and Sanofi SA plan to raise prices in the United States on more than 350 unique drugs in early January, according to data analyzed by healthcare research firm 3 Axis Advisors.

Cellectis logo

French biotech Cellectis said on Thursday it will take a 19% stake in the gene-editing technology startup Primera Therapeutics, launched by the private firm Mayflower Bioventures.

The U.S. Food and Drug Administration failed to adhere to its own guidance and internal practices during the approval process for Biogen’s Alzheimer’s drug Aduhelm, which was “rife with irregularities,” a congressional report showed on Thursday.

blister packets

The U.S. government on Thursday filed a civil lawsuit accusing the drug distributor AmerisourceBergen Corp. of contributing to the deadly U.S. opioid epidemic by repeatedly failing to report suspicious orders of prescription painkillers.

Pfizer logo

U.S. drugmaker Pfizer Inc. said on Thursday its experimental gene therapy for the treatment of hemophilia B, a rare inherited blood disorder, met its main goal in a late-stage study.

Novartis AG said on Wednesday it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in the United States of generic versions of its Exforge hypertension drug.

Hong Kong International Airport

Hong Kong will cancel its stringent COVID-19 rules from Thursday, city leader John Lee said, meaning that arrivals will no longer need to do mandatory PCR tests while the city’s vaccine pass would also be scrapped.